Scarica l'app Stockscreener
1.29
0.00%
0.00
Dopo l'orario di chiusura:
1.26
-0.03
-2.33%
Precedente Chiudi:
$1.29
Aprire:
$1.28
Volume 24 ore:
75,875
Relative Volume:
0.58
Capitalizzazione di mercato:
$88.72M
Reddito:
-
Utile/perdita netta:
$-9.22M
Rapporto P/E:
-4.4224
EPS:
-0.2917
Flusso di cassa netto:
$-4.60M
1 W Prestazione:
+5.74%
1M Prestazione:
-7.86%
6M Prestazione:
-2.27%
1 anno Prestazione:
-38.57%
Intervallo 1D:
$1.25
$1.31
Intervallo di 1 settimana:
$1.2001
$1.34
Portata 52W:
$1.05
$3.10
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Nome
Telomir Pharmaceuticals Inc
Settore
Industria
Telefono
786-396-6723
Indirizzo
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.29 | 88.72M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-21 | Iniziato | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesEarnings Growth Forecast - Newser
Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike - Stock Titan
Telomir Pharmaceuticals (TELO) director resets 25K stock options terms - Stock Titan
Telomir Pharmaceuticals Q4 2025 Earnings: Wider-than-Expected Loss as Revenue Remains AbsentRising Community Picks - Newser
Telomir Pharmaceuticals (TELO) Stock Analysis: -4.96% Down — Bearish Signals to Watch 2026-05-21Smart Money Flow Stocks - Newser
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Improves Survival and Liver Outcomes in Wilson’s Disease Model - Minichart
Telomir Pharmaceuticals publishes peer-reviewed study on Telomir-Zn for Wilson disease - Traders Union
Telomir-Zn Preclinical Data Published in Wilson’s Disease - TipRanks
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease - ACCESS Newswire
Wilson’s disease study backs Telomir-Zn for Telomir (NASDAQ: TELO) - Stock Titan
Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Pharmaceuticals (TELO) Q4 2025 Disappoints — EPS $-0.28 Below $-0.07 ViewsEBITDA Margin Trends - Newser
Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary - TradingView
Telomir (NASDAQ: TELO) closes TELI deal amid Q1 loss and cash risk - Stock Titan
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
GLP safety trials find Telomir 1 well tolerated, Telomir Pharmaceuticals, Inc. asserts - Traders Union
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study - Sahm
Telomir Pharmaceuticals Receives FDA Clearance for IND of Telomir-Zn in Phase 1/2 Trial for Triple-Negative Breast Cancer 8 - Minichart
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer - marketscreener.com
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn - TipRanks
Telomir Pharmaceuticals (TELO) wins FDA IND clearance for Telomir‑Zn Phase 1/2 cancer trial - Stock Titan
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - Corsicana Daily Sun
FDA IND clearance puts Telomir's TNBC drug into first human testing - Stock Titan
Telomir shares surge after breakthrough tumor suppressor gene reactivation data - MSN
Telomir (TELO) CEO Aminov issued 7,319,710 shares in TELI acquisition - Stock Titan
Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Lead Drug Telomir-1 - citybuzz -
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition By Investing.com - Investing.com India
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals and Files Form 8-K with Nasdaq Listing - Minichart
Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights - TipRanks
Telomir completes acquisition of TELI Pharmaceuticals - Investing.com
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition - Investing.com
Telomir completes acquisition of TELI Pharmaceuticals By Investing.com - Investing.com UK
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares - TradingView
Telomir (NASDAQ: TELO) closes TELI acquisition, issues 34,389,710 shares and adds funding - Stock Titan
Telomir locks up worldwide rights to its lead drug, with $1M now and $4M tied to milestones - Stock Titan
TELO Telomir Pharmaceuticals gains slightly even as Q4 2025 EPS lands far below analyst consensus estimates.Community Sell Signals - Xã Thanh Hà
Telomir Pharmaceuticals unveils preclinical data for Telomir-1 at AACR Annual Meeting - Traders Union
Telomir Pharmaceuticals (TELO) Stock: Is It a Compelling Buy (Tumbles Hard) 2026-04-20Analyst Consensus - Xã Vĩnh Công
Telomir Pharmaceuticals (TELO) Stock: Why You Should Hold It (+2.29%) 2026-04-15Expert Entry Points - Xã Thanh Hà
Is Telomir Pharmaceuticals (TELO) Stock Lagging the Market | Price at $1.25, Up 2.46%Community Chart Signals - Newser
Sentiment Review: Will Telomir Pharmaceuticals Inc outperform small cap indexesPortfolio Risk Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: How does Telomir Pharmaceuticals Inc compare to its peers2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Is Telomir Pharmaceuticals (TELO) Stock Growing Now | Price at $1.30, Up 2.36%Shared Momentum Picks - Newser
TELO SEC FilingsTelomir Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
Is Telomir Pharmaceuticals (TELO) Stock defensive in downturns | Price at $1.27, Down 3.79%Max Pain Level - Newser
Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC - BioWorld News
Telomir Pharmaceuticals Inc Azioni (TELO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):